2025 proved to be a tumultuous year for the UK biotech industry, yet it closed with emerging signs of optimism and renewed investor interest. This shift is notable, especially given the prior year’s robust performance, which saw 113 deals finalized. In stark contrast, 2025 recorded a significant drop in deal activity and financing.
Declining Deal Counts
The total number of deals in 2025 fell sharply, reflecting a broader trend of caution within the sector. Overall equity financing plummeted by 49%, totaling £1.9 billion, while follow-on financing in public markets saw a staggering 94% decrease, dwindling to just £96 million. Such figures underscore the current challenges facing biotechs as they navigate a complex financial landscape.
Concentration of Venture Capital
Interestingly, two major venture capital deals involving Isomorphic Labs and Verdiva Bio represented an impressive 44% of the year’s total venture capital raised. This concentration elevated the average deal size from £18.7 million in 2024 to £30.8 million in 2025. While this signals a strategic focus on larger, more impactful investments, it also highlights the risks associated with limited funding avenues.
A Glimmer of Hope
Despite the overall downturn, the final quarter of 2025 brought a surge in venture capital activity, with 22 deals completed. The British Investment Association (BIA) remains optimistic that this uptick could signify a shift in investor sentiment as the sector heads into 2026. Such developments might foster a more robust investment climate, encouraging a return to more diverse funding opportunities.
M&A Activity on the Rise
The absence of initial public offerings (IPOs) for UK biotech firms extended into a third consecutive year. However, mergers and acquisitions (M&A) experienced a notable increase. High-profile transactions included the acquisition of Verona Pharma by MSD, valued at £7.5 billion, and Sanofi’s £1.2 billion takeover of Vice Bio. These transactions reflect a strategic pivot within the industry, where larger firms are seeking innovation-driven growth through acquisitions.
Strategic Maturation
According to BIA managing director Jane Wall, 2025 was characterized as “a year of caution and strategic maturation.” She emphasized that the investment landscape is one of the most selective seen in the past decade. This selectivity suggests that investors are becoming increasingly discerning, concentrating their capital on fewer, more promising ventures. Wall also pointed out the crucial need for governmental support to sustain the biotech sector, underscoring the importance of fostering domestic investment.
International Dynamics
The geopolitical climate has added complexity to the investment landscape. Wall noted that international capital continues to dominate later-stage financing, creating an urgent mandate for the UK government to bolster support for this vital economic sector. Encouraging domestic investors to engage with the biotech industry remains paramount, especially as global competition intensifies.
UK’s Leading Position
On a positive note, the UK has maintained its status as Europe’s foremost biotech hub, securing 30% of all European venture financing. The BIA anticipates that rising sentiment toward biotech—exemplified by the Nasdaq reaching an all-time high—will usher in a healthier capital distribution across the biotech ecosystem in 2026. This resilience positions the UK to effectively combat the current financial headwinds.
Looking Ahead
As the UK biotech sector prepares for the challenges and opportunities of 2026, the focus will be on fostering a supportive environment for innovation and investment. The collective efforts of stakeholders, including the government and private investors, will be crucial in determining the trajectory of the industry.
In conclusion, while 2025 was marked by financial challenges and a decline in overall activity, the UK biotech sector demonstrates resilience and potential for recovery. The final quarter’s surge in venture capital activity, combined with strategic mergers and acquisitions, lays a solid foundation for future growth. With renewed investor confidence and strategic support, the prospects for 2026 appear promising.
- UK biotech experienced a significant decline in financing in 2025, with a 49% drop to £1.9 billion.
- Two major VC deals accounted for 44% of total venture capital raised, raising average deal sizes significantly.
- M&A activity increased, with notable acquisitions like MSD’s buyout of Verona Pharma.
- The UK retains its position as Europe’s leading biotech market, capturing 30% of venture financing.
- The sector anticipates improved investor sentiment and capital distribution in 2026.
Read more → pharmaphorum.com